Annual performance PK of multinational pharmaceutical companies!

According to the 2021 financial reports released by multinational pharmaceutical companies, the rankings have once again ushered in a reshuffle
.
Although Pfizer's detailed financial report has not yet been seen, with the new crown pneumonia vaccine, Pfizer can regain the throne without any suspense
.
Driven by the rapid growth of blockbuster products, AbbVie and Johnson & Johnson saw their performance rise
.
The inventory found that the top four multinational pharmaceutical companies have all exceeded the US$50 billion mark, and Pfizer is advancing towards 100 billion
.
01.
Pfizer: New crown vaccine + oral drugs drive performance soaring Pfizer CEO Albert Bourla said that Pfizer’s sales in 2021 are expected to exceed $80 billion, the highest annual figure ever
.
Analysts expect Pfizer's revenue to exceed $100 billion in 2022 as it ramps up production of its oral antiviral drug Paxlovid
.
The new crown vaccine developed by Pfizer and Germany's BioNTech is expected to have sales of $36 billion in 2021 and $29 billion in 2022
.
Analysts forecast Paxlovid's sales this year to be close to $23 billion
.
The industry also believes that Pfizer will continue to vigorously carry out mergers and acquisitions in the next few years
.
02.
AbbVie: Rapid growth of a number of blockbuster products AbbVie’s total revenue in 2021 will be US$56.
197 billion, a year-on-year increase of 22.
7%, mainly driven by performance in the fields of autoimmune diseases and hematological tumors, and the share of autoimmune diseases is close to half
.
Humira (adalimumab) sales increased by 3.
5%, and sales exceeded the $20 billion mark
.
Humira will lose its exclusivity in the US market in 2023, and sales may face a sharp decline
.
In 2021, the performance of AbbVie's various products will increase rapidly.
The sales of Skyrizi (resalizumab) will be 2.
939 billion US dollars, an increase of 84.
9% year-on-year; the sales of neurological disease drug Vraylar (cariprazine) will be 1.
728 billion US dollars, A year-on-year increase of 81.
7%; the revenue of the oral JAK1 inhibitor Rinvoq (upatinib) reached US$1.
65 billion, a year-on-year increase of over 100%
.
AbbVie has taken a variety of measures to expand its product line and get rid of the possible decline in performance after Humira loses market exclusivity
.
At the same time, its medical beauty performance is gratifying, and it is expected that by 2029, sales will reach 9 billion US dollars
.
03.
Johnson & Johnson: major restructuring, focus on cutting-edge innovation In 2021, Johnson & Johnson will achieve total revenue of US$93.
775 billion, a year-on-year increase of 13.
6%; of which the pharmaceutical business revenue will be US$52.
08 billion, a year-on-year increase of 14.
3%
.
The growth of the pharmaceutical business was mainly driven by strong growth in the two areas of autoimmune diseases and oncology, including Stelara (ustekinumab), Darzalex (daratumumab), Imbruvica (ibrutinib), Tremfya (old Sekimab), Erleada (apalutamide) and other blockbuster products
.
With its dominant position in Crohn's disease and ulcerative colitis, Stelara has become Johnson & Johnson's most reliant and highest-selling product
.
However, in the next three years, the drug may face the impact of biological drug similar drugs and competing products
.
Erleada, which treats prostate cancer, was the fastest-growing "blockbuster," growing 70 percent to $1.
291 billion in sales
.
Sales of Remicade (infliximab) have declined year after year due to the impact of biosimilars
.
Remicade peaked at $7 billion in 2016; shrinks to $3.
19 billion in 2021, down 14.
9% year-on-year
.
At the end of last year, Johnson & Johnson announced the largest structural adjustment in 135 years.
It plans to split the group into two parts.
The pharmaceutical and medical device businesses will be merged into a new Johnson & Johnson company, of which pharmaceuticals account for 65% and devices account for 35%; the consumer health business will become an independent company.
new company
.
Johnson & Johnson aims to achieve $60 billion in drug sales by 2025
.
04.
Novartis: Gene therapy has entered the ranks of "blockbusters" Novartis' net sales revenue in 2021 will reach US$51.
626 billion, a year-on-year increase of 6%
.
The sales revenue in the Chinese market was US$3.
052 billion, accounting for 6% of the global total
.
Novartis' performance was mainly driven by strong growth in products such as Cosentyx (secukinumab) and new heart failure drug Entresto (sacubitril-valsartan)
.
Cosentyx achieved full-year revenue of $4.
718 billion, an increase of 18% year-on-year, and was Novartis' top-selling product
.
Entresto fared even better, with sales reaching $3.
548 billion, an increase of 42%
.
The gene therapy Zolgensma is Novartis' fastest-growing blockbuster drug, with sales revenue reaching $1.
351 billion in 2021, a year-on-year increase of 47%, and the drug has been approved in 42 countries
.
It is understood that Novartis will continue to maintain a "balanced" capital allocation
.
It previously sold its long-held Roche stake for $20.
7 billion
.
Recently, it was reported that private equity firms Blackstone Group and The Carlyle Group may join forces to acquire Sandoz, a generic drug company owned by Novartis, for $25 billion
.
A research firm said that if Sandoz were sold or split, Novartis would earn higher profits and possibly generate higher returns on capital
.
05.
Roche: Oncology business declines Roche’s total revenue in 2021 is 62.
801 billion Swiss francs (about 69.
012 billion US dollars), a year-on-year increase of 9.
3%
.
Among them, the pharmaceutical business revenue was 45.
041 billion Swiss francs (about 49.
496 billion US dollars), a year-on-year increase of 3.
1%
.
The pharmaceutical business revenue in China was 3.
276 billion Swiss francs, accounting for 7.
3% of the pharmaceutical business revenue
.
The oncology business fell 11%, dragging down pharma results
.
In recent years, the sales of Roche's anticancer drug "troika" have further fallen sharply, with sales of Avastin (bevacizumab), Herceptin (trastuzumab) and Rituxan (rituximab) falling respectively in 2021 38%, 37% and 28%, compared with 2020, a total decrease of nearly 4.
2 billion Swiss francs in revenue
.
The PD-L1 monoclonal antibody Tecentriq (atezolizumab) slowed down, up 21% year-on-year
.
Multiple sclerosis drug Ocrevus carried the banner with sales of CHF 5.
055 billion, an increase of 19%, making it Roche's highest-selling product
.
The hemophilia drug Hemlibra (emerizumab) grew strongly, with sales up 41% to CHF 3.
022 billion, making it Roche's fastest-growing blockbuster product
.
This year, Roche expects sales to remain stable or grow in the low single digits
.
The sales of medicines and diagnostics related to the new crown epidemic are expected to fall to 2 billion to 5 billion Swiss francs, and the sales loss caused by biosimilars is about 2.
5 billion Swiss francs
.
06.
BMS: O drugs resume positive growth Bristol-Myers Squibb (BMS)’s total revenue in 2021 will be US$46.
385 billion, a year-on-year increase of 9%
.
The growth of BMS performance mainly comes from Revlimid (lenalidomide), Eliquis (apixaban), Opdivo (nivolumab), Orencia (abatacept), Pomalyst/Imnovid (pomalidomide), Sprycel (da Satinib), Yervoy (ipilimumab) and Abraxane (albumin-paclitaxel), these eight blockbuster products have combined sales of more than $43 billion, accounting for 93% of total revenue
.
The sales of Revlimid and Eliquis both exceeded US$10 billion, achieving growth of 6% and 17% respectively
.
However, Revlimid will lose market exclusivity this year, and sales are expected to decline
.
The star anti-tumor drug "O drug" nivolumab was affected by the epidemic in 2020, and its sales declined for the first time.
It will resume positive growth in 2021, with a year-on-year increase of 8%, and its sales will reach 7.
523 billion US dollars
.
BMS expects blockbusters such as Opdivo and Eliquis to remain active in the coming years, with multi-billion-dollar sales growth by 2025
.
Despite competition from generics and biosimilars, BMS said the company will grow by expanding its major branded products and advancing its pipeline, with a new product portfolio that could generate $25 billion or more by 2029, while its positive It plans to bring 7 products in the middle and late stage of development to the market
.
07.
Merck: The Chinese market will grow by 60%.
Merck's pharmaceutical business sales revenue in 2021 will reach US$42.
754 billion, a year-on-year increase of 17%
.
Merck China also became the best-performing region in the world, with total revenue reaching US$4.
262 billion, a year-on-year increase of 60%
.
Merck's performance was mainly driven by Keytruda and HPV vaccine sales
.
In 2022, Keytruda is expected to surpass the $20 billion sales mark
.
In 2028, Keytruda will expire its patent, and Merck is currently trying to break its dependence on Keytruda and seek new growth
.
Merck has also been pushing Keytruda into early-stage therapy as well as various combination therapies
.
In addition, the oral new crown drug molnupiravir, which was emergency authorized for use in November 2021, also contributed $952 million in revenue
.
Merck forecasts molnupiravir sales to reach $5 billion to $7 billion in 2022
.
Merck expects global sales to be between $56.
1 billion and $57.
6 billion in 2022
.
08.
Sanofi: Launching a new LOGO and adjusting the R&D pipeline Sanofi’s net income in 2021 will be 37.
761 billion euros, a year-on-year increase of 7.
1%
.
Revenues from the Pharmaceuticals and Vaccines businesses combined totaled 33.
293 billion euros (approximately $38 billion)
.
Revenue from China was 2.
720 billion euros, a year-on-year increase of 7.
9%
.
Dupixent (duprilumab) continued to maintain rapid growth, with an increase of 52.
7%, and sales revenue reached 5.
249 billion euros, becoming Sanofi's blockbuster product with the highest sales and fastest growth rate
.
Recently, Sanofi launched a new brand image, and the company's executives also reiterated the remodeling strategy and adjusted the R&D pipeline
.
On January 6, Sanofi terminated its partnership with Sangamo Therapeutics to develop personalized cell therapies
.
09.
Eli Lilly: Maintaining its Advantage in Diabetes Field Eli Lilly’s total revenue in 2021 will be US$28.
318 billion, a year-on-year increase of 15%
.
Revenue in China was US$1.
661 billion, an increase of 49%
.
Diabetes and tumor drugs are the main growth drivers.
The annual revenue of Trulicity (dulaglutide) was US$6.
472 billion, a year-on-year increase of 28%
.
CDK4/6 inhibitor Verzenio (Abexili) sales were $1.
35 billion, up 48% year-on-year
.
COVID-19 neutralizing antibodies also brought in $2.
239 billion
.
10.
Gilead: Expanding oncology business Gilead's total revenue in 2021 will be US$27.
305 billion, an increase of 11% year-on-year
.
The three-in-one HIV drug Biktarvy has become the core pillar product of Gilead, with sales revenue reaching US$8.
624 billion, a year-on-year increase of 19%
.
New crown drug Veklury (remdesivir) sales revenue surged 98% to $5.
56 billion
.
In the future, Gilead hopes to continue to expand its leadership in the antiviral field; extensively expand its oncology business, which currently accounts for 30% of its sales
.